التفاصيل البيبلوغرافية
| العنوان: |
Belantamab mafodotin detection by MASS-FIX and immunofixation. |
| المؤلفون: |
Mellors, Patrick W., Kohlhagen, Mindy C., Dasari, Surendra, Willrich, Maria A. V., Gertz, Morie A., Kumar, Shaji K., Lacy, Martha Q., Murray, David L., Dispenzieri, Angela |
| المصدر: |
Clinical Chemistry & Laboratory Medicine; 2021, Vol. 59 Issue 11, pe430-e433, 4p |
| مصطلحات موضوعية: |
MONOCLONAL antibodies, DESORPTION ionization mass spectrometry |
| مستخلص: |
Notably, however, IFE did not detect BM in the same IgG lambda MM patient with hypogammaglobulinemia spiked at I C i SB max sb , or in any of the three patients receiving BM. (E) IFE of BM spiked at Cmax of 42 mcg/mL in the same IgG lambda MM patient from panel C. (F-H) IFE of 3 myeloma patients on BM therapy (Table 1, patients 2, 3, and 4, respectively). Keywords: belantamab mafodotin; immunofixation; mass spectrometry; multiple myeloma EN belantamab mafodotin immunofixation mass spectrometry multiple myeloma e430 e433 4 10/18/21 20210915 NES 210915 To the Editor, Monoclonal antibodies (mAbs) such as daratumumab and elotuzumab have emerged as novel, effective therapies for relapsed/refractory multiple myeloma (MM). [Extracted from the article] |
|
Copyright of Clinical Chemistry & Laboratory Medicine is the property of De Gruyter and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
